Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.
The aim of the study was to determine possible factors related to the risk of developing recurrent bacterial respiratory tract infections in HIV-1-infected patients, regardless of the degree of immune cellular impairment. Thirty-three HIV-1 seropositive patients with previous repetitive bacterial respiratory tract infections (case group), 33 HIV-1 seropositive controls (matched by CD4-cell counts) without these antecedents and 27 healthy controls were studied before and after administration of pneumococcal and Haemophilus influenzae type b vaccines. Clinical or toxicological variables, cutaneous tests, complement factors, beta2-microglobulin, serum IgM, IgA, IgG and subclasses, specific antibodies (IgG, IgG2, IgA) against pneumococcal vaccine and polyribosylribitol phosphate (PRP), their avidity, opsonophagocytosis and IgG(2)m and Fc(gamma)RIIa allotypes were determined. A history of drug abuse (P = 0.001), less likelihood of receiving high activity antiretroviral treatment high activity antiretroviral treatment (HAART) (P = 0.01), higher levels of HIV-1 viral load (P < 0.05), serum IgG (P < 0.01) and beta2-microglobulin (P < 0.01) were observed in the case group. Also, a lower increase in specific antibodies to pneumococcal vaccine and PRP was demonstrated in the cases in comparison with the two control groups. No differences were observed in the avidity of antibodies, opsonophagocytic capacity or IgG(2)m and Fc(gamma)RIIa allotypes between the three groups. These data indicate that vaccination strategies against encapsulated bacteria can be unsuccessful in the HIV-1-infected patients presenting repetitive bacterial respiratory tract infections if behavioural aspects or measures to improve adherence to HAART therapies are not considered.
Payeras
A
A
Infectious Diseases Units, Hospital Son Dureta and Fundació Hospital Son Llatzer, Palma de Mallorca, Balears, Spain. apayeras@fhsonllatzer.org
Martinez
P
P
Milà
J
J
Riera
M
M
Pareja
A
A
Casal
J
J
Matamoros
N
N
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood* / Q000145:classification / Q000276:immunology; D015703:Antigens, CD / Q000235:genetics; D023241:Antiretroviral Therapy, Highly Active; D016022:Case-Control Studies; D003710:Demography; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1; D018073:Haemophilus Vaccines / Q000276:immunology; D006801:Humans; D007126:Immunoglobulin Allotypes; D008297:Male; D008875:Middle Aged; D009895:Opsonin Proteins / Q000378:metabolism; D010587:Phagocytosis; D022242:Pneumococcal Vaccines / Q000276:immunology; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D012307:Risk Factors
D000907:Antibodies, Bacterial; D015703:Antigens, CD; C080568:Fc gamma receptor IIA; D018073:Haemophilus Vaccines; D007126:Immunoglobulin Allotypes; D009895:Opsonin Proteins; D022242:Pneumococcal Vaccines; D017452:Receptors, IgG